OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Cancer is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Subscription & copyright page	274
FBXW10: a male-biased E3 ligase in liver cancer	264
Engineering growth factor ligands and receptors for therapeutic innovation	250
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	242
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	216
Revumenib: a new era in acute leukemia treatment	211
Advancements in organoid models emulating metastatic niches	210
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	201
Spliced to kill: RNA mis-splicing derived cancer neoantigens	199
Platelets: tailoring metastasis treatment	189
Tumor-resident microbes: the new kids on the microenvironment block	185
Navigating life as an early career researcher	177
Subscription & copyright page	167
Subscription and copyright page	165
Advisory Board and Contents	159
Leveraging circulating microbial DNA for early cancer detection	157
Onco-condensates: formation, multi-component organization, and biological functions	152
Accessing the vasculature in cancer: revising an old hallmark	144
Engine shutdown: migrastatic strategies and prevention of metastases	143
Subscription & copyright page	131
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	115
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	115
From prediction to precision: how immunopeptidomics advances neoantigen discovery	108
Gut microbiota – a double-edged sword in cancer immunotherapy	107
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	105

The evolving landscape of brain metastasis: volume II	103
Oncogenic competence: balancing mutations, cellular state, and microenvironment	102
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	101
Diet, nutrient supply, and tumor immune responses	99
Chromatin as an old and new anticancer target	94
Regulation of metastatic organotropism	92
Recent developments in myeloid immune modulation in cancer therapy	86
GOT2 consider the tumor microenvironment	83
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	80
FGFR rearrangements: oncogenic drivers and therapeutic targets	79
Benefits and opportunities of the transgenic Oncopig cancer model	77
Crosstalk of T cells within the ovarian cancer microenvironment	76
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	74
Circulating tumor DNA in biliary tract cancers: challenges, opportunities, and clinical readiness	73
Cell death, therapeutics, and the immune response in cancer	71
Neural hijacking in cancer metabolism: from nutrients to organelles	70
Advisory Board and Contents	69
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	66
Subscription & copyright page	66
Palmitate paves the way to lung metastasis	65
Insights on ErbB glycosylation – contributions to precision oncology	65
Scaling data toward pan-cancer foundation models	63
Genetic immune escape in cancer: timing and implications for treatment	63
Toward mutational epidemiology: using mutational signatures of environmental exposures to assess cancer risk	61
Organellar pH as an emerging vulnerability to exploit in cancer	61
Planning for cancer: building accessible and high-quality survivorship care for all	61
The emerging field of oncolytic virus-based cancer immunotherapy	61
Inflammation: the incubator of the tumor microenvironment	60
Clinical and translational relevance of intratumor heterogeneity	59
Subscription & copyright page	57
Advisory Board and Contents	56
Advisory Board and Contents	56
Advisory Board and Contents	56
Advisory Board and Contents	55
Advancing cancer precision surgery with the tumor coagulome	55
Emerging mechanisms of telomerase reactivation in cancer	54
Prospects for understanding and exploiting the consequences of hyperactivation lethality	53
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	51
Microbiome: a driver of pancreatic inflammation and tumorigenesis	50
Circulating cell-free DNA-based multi-cancer early detection	50
B7-H3: a robust target for immunotherapy in prostate cancer	49
RHOA takes the RHOad less traveled to cancer	49
Cuproptosis in cancer: from molecular mechanisms to therapeutic intervention	49
Updating cancer research with patient-focused networks	49
Molecular and clinical insights into early-onset endometrial cancer	48
Gut microbial metabolites for potentiating cancer therapy	48
Stress granules and hormetic adaptation of cancer	47
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	47
Advisory Board and Contents	47
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	47

Advisory Board and Contents	46
A macrophage-neutrophil program drives mammary carcinogenesis	46
Advisory Board and Contents	45
Subscription & copyright page	45
Time-of-day dependency of adoptive cell therapies	43
Neoantigen-directed therapeutics in the clinic: where are we?	43
Beyond safety: suicide systems in cell-based cancer therapies	43
Mechanistic cancer prevention comes of age	43
Subscription & copyright page	43
Orchestrating tumor-immune epigenetics via SERT–H3Q5ser axis	43
The promise of TIL therapy for glioblastoma	43
Targeting TIM-3 to halt lung precancer progression	43
Advisory Board and Contents	43
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	42
Branched chain amino acids and their aberrant metabolism in cancer	40
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	40
Leveraging space innovations for cancer breakthroughs on Earth	39
RNA vaccines for cancer: revolutionizing immunization strategies	39
CAR T cell persistence in cancer	37
Functional heterogeneity of fibroblasts in primary tumors and metastases	37
Advisory Board and Contents	35
Subscription & copyright page	35
Ferroptosis vulnerability in FLT3-mutant leukemia	35
Advisory Board and Contents	34
Space in cancer biology: its role and implications	34
Engineered bacterial therapeutics for detecting and treating CRC	34
ApCAFs: spatial niches and therapeutic insights across cancers	34
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	33
Dying to survive: harnessing inflammatory cell death for better immunotherapy	33
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	33
Neural circuits in lung adenocarcinoma modulate immunosurveillance	32
Advisory Board and Contents	32
Advisory Board and Contents	32
Advisory Board and Contents	31
Dissecting histological transformation	31
Clonal evolution and hierarchy in myeloid malignancies	31
Subscription & copyright page	31
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	30
Genitourinary cancer neoadjuvant therapies: current and future approaches	30
Addressing the genetic/nongenetic duality in cancer with systems biology	30
Subscription & copyright page	30
Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics	29
Mesothelioma: a systemic therapy clinical trials snapshot	29
The development of therapy related myeloid neoplasms in childhood cancer survivors	28
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	28
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	28
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	27
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	27
Next-generation cancer vaccines and emerging immunotherapy combinations	26
Lifileucel: the first cellular therapy approved for solid tumours	26
Immunomodulation by endothelial cells: prospects for cancer therapy	26
NETscape or NEThance: tailoring anti-cancer therapy	26
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	25
Subscription & copyright page	25
Successfully targeting the cancer system with metronomics for medulloblastoma	25
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome	24
How DNA methylation predicts response to cancer therapies	24
Persisting cancer cells are different from bacterial persisters	23
Future perspectives on engineered T cells for cancer	23
The extracellular matrix in cancer: from understanding to targeting	23
Embracing diversity: macrophage complexity in cancer	23
How cancer cells make and respond to interferon-I	22
Subscription & copyright page	22
Tissue architecture in tumor initiation and progression	22
Think zebras: challenges and opportunities for treating rare cancers	22
Deciphering the roles of ABCB5 in normal and cancer cells	22
Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer	21
Towards enhancing the predictive value of the microbiota for cancer immunotherapy	21
Emerging and extensive clonal evolution in the pancreas	21
Extracellular vesicle lipids in cancer immunoevasion	21
Fueling the revolution: RIBOTACs manipulating RNA decay	21